Avidity Biosciences, Inc. (RNA)

Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $3.80 billion. The enterprise value is $2.30 billion.

Market Cap	3.80B
Enterprise Value	2.30B

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

RNA has 120.21 million shares outstanding. The number of shares has increased by 52.83% in one year.

Current Share Class	120.21M
Shares Outstanding	120.21M
Shares Change (YoY)	+52.83%
Shares Change (QoQ)	+4.15%
Owned by Insiders (%)	0.59%
Owned by Institutions (%)	88.54%
Float	92.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	348.60
Forward PS	523.09
PB Ratio	2.66
P/TBV Ratio	2.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	211.44
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.73, with a Debt / Equity ratio of 0.00.

Current Ratio	15.73
Quick Ratio	15.61
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -33.47% and return on invested capital (ROIC) is -24.39%.

Return on Equity (ROE)	-33.47%
Return on Assets (ROA)	-21.60%
Return on Invested Capital (ROIC)	-24.39%
Return on Capital Employed (ROCE)	-25.85%
Revenue Per Employee	$27,870
Profits Per Employee	-$824,302
Employee Count	391
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +28.09% in the last 52 weeks. The beta is 1.02, so RNA's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	+28.09%
50-Day Moving Average	31.45
200-Day Moving Average	38.96
Relative Strength Index (RSI)	50.31
Average Volume (20 Days)	1,342,952

Short Selling Information

Short Interest	16.13M
Short Previous Month	16.95M
Short % of Shares Out	16.52%
Short % of Float	n/a
Short Ratio (days to cover)	12.47

Income Statement

In the last 12 months, RNA had revenue of $10.90 million and -$322.30 million in losses. Loss per share was -$2.89.

Revenue	10.90M
Gross Profit	-292.70M
Operating Income	-378.94M
Pretax Income	-228.68M
Net Income	-322.30M
EBITDA	-376.16M
EBIT	-378.94M
Loss Per Share	-$2.89

Balance Sheet

The company has $1.50 billion in cash and $6.80 million in debt, giving a net cash position of $1.49 billion or $12.43 per share.

Cash & Cash Equivalents	1.50B
Total Debt	6.80M
Net Cash	1.49B
Net Cash Per Share	$12.43
Equity (Book Value)	1.42B
Book Value Per Share	11.89
Working Capital	1.44B

Cash Flow

In the last 12 months, operating cash flow was -$300.87 million and capital expenditures -$7.07 million, giving a free cash flow of -$307.94 million.

Operating Cash Flow	-300.87M
Capital Expenditures	-7.07M
Free Cash Flow	-307.94M
FCF Per Share	-$2.56

Margins

Gross Margin	n/a
Operating Margin	-3,477.43%
Pretax Margin	-2,957.71%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.83%
Shareholder Yield	-52.83%
Earnings Yield	-8.48%
FCF Yield	-8.11%

Analyst Forecast

The average price target for RNA is $68.25, which is 115.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$68.25
Price Target Difference	115.98%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	169.91%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 14.58 and a Piotroski F-Score of 2.

Altman Z-Score	14.58
Piotroski F-Score	2